Crispr Therapeutics AG

CRSP

NASDAQ. Currency in USD

54.34 -0.45 ( -0.82% )

Real time prices: December 01

Market Cap.
4.25B
Beta (5Y monthly)
1.70
Price/Earnings
-
EPS (TTM)
-8.80
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
668,409
1y Target Est.
101.48
Day's Range
53.37
-
55.34
52 Week's Range
42.51
-
86.95

Historical Summary

Performance
EPS growth
Share Buybacks

About Crispr Therapeutics AG

Sector
Healthcare
Industry
Biotechnology
Website
https://www.crisprtx.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
76.53M
Employees
473
Address
Baarerstrasse 14, Zug, Switzerland, 6300
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Latest news

Why Is CRISPR Therapeutics AG (CRSP) Up 0.2% Since Last Earnings Report?
Why Is CRISPR Therapeutics AG (CRSP) Up 0.2% Since Last Earnings Report?

CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We...
By Zacks Investment Research - 16 hours ago

3 Growth Stocks That Are Too Cheap to Ignore
3 Growth Stocks That Are Too Cheap to Ignore

Overlooking these stocks in the current market could be a mistake.
By The Motley Fool - 17 hours ago

2 Stocks Near 52-Week Highs That Could Climb Higher
2 Stocks Near 52-Week Highs That Could Climb Higher

This pair of stocks are bucking the trend and they could climb even higher.
By The Motley Fool - 3 days ago

Cathie Wood Is Selling This High-Flying Stock. Here's Why You Should Buy It Instead
Cathie Wood Is Selling This High-Flying Stock. Here's Why You Should Buy It Instead

The ARK Invest founder might regret trimming her position in this biotech stock.
By The Motley Fool - 6 days ago

What 5 Analyst Ratings Have To Say About CRISPR Therapeutics
What 5 Analyst Ratings Have To Say About CRISPR Therapeutics

CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings within the last quarter: Bullish Somewhat...
By Benzinga - 1 week ago

Where Will Editas Medicine Be in 1 Year?
Where Will Editas Medicine Be in 1 Year?

The company could continue lagging the market for a while.
By The Motley Fool - 1 week ago

2 Growth Stocks That Could Double in 2023
2 Growth Stocks That Could Double in 2023

Both are lagging the market this year.
By The Motley Fool - 2 weeks ago

Crispr Therapeutics Stock: Bull vs. Bear
Crispr Therapeutics Stock: Bull vs. Bear

Crispr shares have fallen about 20% so far this year.
By The Motley Fool - 2 weeks ago